Molecular prototypes with this bivalent mechanism of action should be pivotal to validate the D3R-nAChR complex as an unprecedented therapeutic target for PD and could pave the way for developing original drug candidates in light of a novel pharmacological intervention on the disease. Here, CHRNA4 is linked to Parkinson disease.